Abstracts tagged "pregnancy"

Abstract Number: 0438 • ACR Convergence 2024
Overweight and Obesity Are Key Modifiable Risk Factors for Adverse Outcomes in SLE Pregnancies
Jessica Boivin¹, Karim Sacre², Sasha Bernatsky³, Ann E. Clarke⁴, Megan Barber⁴, Paul Fortin⁵, John Hanly⁶, Alexandra Legge⁷, Sang-Cheol Bae⁸ and Evelyne Vinet⁹, ¹McGill University, Montreal, QC, Canada, ²Université de Paris, Paris, France, ³Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁴Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁵Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, ⁶Dalhousie University, Halifax, NS, Canada, Halifax, NS, Canada, ⁷Dalhousie University, Halifax, NS, Canada, ⁸Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁹McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: High maternal body mass index (BMI) is a well-established modifiable risk factor for adverse pregnancy outcomes (APO) in the general obstetric population. Best practices…
Abstract Number: 0805 • ACR Convergence 2024
Results from the Certolizumab-pegol Pregnancy Exposure Registry: An OTIS Autoimmune Diseases in Pregnancy Project
Christina Chambers¹, Jane Adams², Ronghui Xu³, Diana Johnson³, Yunjun Luo³ and Kenneth Jones³, and the OTIS collaborative research group, ¹University of California, San Diego, La Jolla, CA, ²Department of Psychology, University of Massachusetts, Boston, MA, ³University of California San Diego, La Jolla, CA
Background/Purpose: Certolizumab pegol (CZP) is a tumor necrosis factor (TNF) blocker first approved in the U.S. in 2008. CZP is approved for the treatment of…
Abstract Number: 2165 • ACR Convergence 2024
Fertility Concerns in Adolescents and Young Adults Receiving Gonadotoxic Medications for Rheumatic Disease
SHAHD FARAJALLAH¹, Katie Dunnock², Qing Yu³, Sangeeta Sule⁴ and Tova Ronis⁴, ¹Children's national hospital, Washington DC, ²George Washington University, washington dc, ³George Washington University, washington dc, DC, ⁴Children's National Hospital, Washington, DC
Background/Purpose: Adolescents and young adults diagnosed with rheumatic diseases often require treatment with teratogenic and cytotoxic medications to effectively manage their conditions. While these therapies…
Abstract Number: 0184 • ACR Convergence 2024
Improving Age Disparities in Contraceptive Counseling in Women with Lupus: A Quality Improvement Initiative
Hillary Weisleder¹, Chinenye Osuorji², Melissa Fazzari³, Ying Jin² and Bibi Ayesha², ¹Montefiore Einstein, New York, NY, ²Montefiore Medical Center, Bronx, NY, ³Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Lupus is an autoimmune disease primarily affecting women of reproductive age. Lupus confers an increased risk of adverse maternal fetal outcomes, and pre-pregnancy planning…
Abstract Number: 0439 • ACR Convergence 2024
Contraception Counseling and Contraception Use Among SLE and RA/JIA Patients at a Public Medical Center in Los Angeles: Investigating Teratogenic Medication Use and Language Preferences
Laura Kobashigawa¹, Cassidy Hernandez-Tamayo², Katherine Ruddy³, Melissa Wilson² and Leanna Wise⁴, ¹University of Southern California/Los Angeles General Medical Center, Pasadena, CA, ²Keck School of Medicine of USC, Los Angeles, CA, ³University of Southern California/ Los Angeles General Medical Center, Los Angeles, CA, ⁴LAC+USC/Keck Medicine of USC, Pasadena, CA
Background/Purpose: Systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)/juvenile idiopathic arthritis (JIA) frequently impact women of reproductive age. Management of these patients is particularly important…
Abstract Number: 0806 • ACR Convergence 2024
Rotavirus Vaccine in Offspring Exposed to Tumour Necrosis Factor Inhibitors During the Third Trimester Does Not Increase Diarrhea-Associated Healthcare Events
Leah K. Flatman¹, Sasha Bernatsky², Isabelle Malhamé³, Yvan St-Pierre⁴, Olga Basso¹, Anick Bérard⁵ and Evelyne Vinet³, ¹McGill University, Montreal, QC, Canada, ²Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³McGill University Health Centre, Montreal, QC, Canada, ⁴McGill University Health Center, Montreal, QC, Canada, ⁵Université de Montréal, Montreal, QC, Canada
Background/Purpose: Until recently, best practice guidelines recommended withholding rotavirus vaccine in offspring exposed in utero to any TNFi until 6 months of age due to fears of…
Abstract Number: 2398 • ACR Convergence 2024
The Relationship Between First-Trimester Maternal Serum 25-Hydroxyvitamin D and Maternal/Fetal Outcomes in Patients with Systemic Lupus Erythematosus
wen zeng¹, Yuanyuan zeng¹, Lan Zhang², Cheng Zhao¹, Fang Qin¹, Leting Zheng², Mu Huang² and ling lei¹, ¹The First Affiliated Hospital of Guangxi Medical University, nanning, China (People's Republic), ²The First Affiliated Hospital of Guangxi Medical University, nanning, Guangxi, China (People's Republic)
Background/Purpose: To identify whether serum 25-Hydroxyvitamin D (25(OH)D) level in first-trimester(before13 weeks of gestation) maternal is associated with pregnancy outcomes in patients with systemic lupus…
Abstract Number: 0191 • ACR Convergence 2023
Reproductive Health Discussions Between Rheumatology Providers and Systemic Lupus Erythematosus Patients: A Survey of English and Spanish-Speaking Patients
Meredith Xepoleas¹, Martha Delgado², Jack Rodman³, Julia Simard⁴, Sandy Lee⁵ and Leanna Wise⁶, ¹Keck School of Medicine of University of Southern California, Los Angeles, CA, ²LAC+USC/Keck School of Medicine, Los Angeles, CA, ³University of Southern California, Los Angeles, CA, ⁴Department of Epidemiology & Population Health, Stanford University School of Medicine, Stanford, CA, ⁵University of Southern California, Walnut, CA, ⁶LAC+USC/Keck Medicine of USC, Pasadena, CA
Background/Purpose: Systemic lupus erythematosus (SLE) primarily affects women of childbearing age, with a higher burden in non-Caucasian populations. Due to the increased risk of adverse…
Abstract Number: 0722 • ACR Convergence 2023
Acute Cardiovascular Events in Autoimmune Rheumatic Disease Pregnancies
Rashmi Dhital¹, Rebecca Baer², Monica Guma², Kenneth Kalunian², Accelerating Medicines Partnership Program RA SLE Network³ and Christina Chambers², ¹UC San Diego, San Diego, CA, ²University of California San Diego, La Jolla, CA, ³Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose: Cardiovascular diseases (CVDs) complicate 1-4% of pregnancies. Autoimmune rheumatic diseases (ARDs) are associated with a 1.5 to 3-fold higher CVD risk. Similarly, antiphospholipid syndrome…
Abstract Number: 1362 • ACR Convergence 2023
Improving Reproductive Health Counseling for Pediatric Adolescent Females Prescribed Teratogenic DMARDs
Rina Ferguson¹, Itay Marmor² and Maleewan Kitcharoensakkul¹, ¹Washington University/B-JH/SLCH Consortium, St. Louis, MO, ²Dana-Dwek Children's Hospital, Hod Hasharon, Israel
Background/Purpose: Several rheumatologic medications routinely prescribed to adolescent females are teratogenic. However, there is no standard method to educate our patients and their families about…
Abstract Number: 0194 • ACR Convergence 2023
Reproductive Health Conversations with a Primarily Hispanic Systemic Lupus Erythematosus Population: Influences and Barriers
Zarmeen Zaheer¹, Martha Delgado², Jack Rodman³, Julia Simard⁴, Sandy Lee⁵ and Leanna Wise⁶, ¹Huntington Health, Tampa, FL, ²LAC+USC/Keck School of Medicine, Los Angeles, CA, ³University of Southern California, Los Angeles, CA, ⁴Department of Epidemiology & Population Health, Stanford University School of Medicine, Stanford, CA, ⁵University of Southern California, Walnut, CA, ⁶LAC+USC/Keck Medicine of USC, Pasadena, CA
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease most commonly seen in women of childbearing age, with a greater burden in non-Caucasian populations. The…
Abstract Number: 0903 • ACR Convergence 2023
Effects of Hydroxychloroquine on Maternal Outcomes in Pregnant Patients with Systemic Lupus Erythematous
Yurilu Gonzalez¹ and Irene Tan², ¹Albert Einstein Medical Center, Wyncote, PA, ²Einstein Medical Center Philadelphia, Bala Cynwyd, PA
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease, that affects women of childbearing age. SLE is a high-risk condition in pregnant patients due…
Abstract Number: 1364 • ACR Convergence 2023
Both Low and High 25(OH)-Vitamin D Levels Increase Adverse Pregnancy Outcomes in Systemic Lupus Erythematosus
Nima Madanchi¹, Andrea Fava², Daniel Goldman³, Larry Magder⁴, Rebecca Jacobson¹ and Michelle Petri³, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ⁴University of Maryland, Baltimore, MD
Background/Purpose: We evaluated the role of maternal 25(OH)-vitamin D in adverse pregnancy outcomes in systemic lupus erythematosus (SLE). Methods: We used a longitudinal cohort that…
Abstract Number: 0463 • ACR Convergence 2023
Appropriate Preconception Care Improves Pregnancy Outcomes in SLE Patients
Hiromi Shimada¹, Rina Mino², Risa Wakiya³, Shusaku Nakashima³, Taichi Miyagi⁴, Yusuke Ushio⁵, Koichi Sugihara⁶, Mao Mizusaki³, Kanako Chujo⁷, Ryoko Kagawa⁵, Hayamasa Yamaguchi⁵, Tomohiro Kameda³ and Hiroaki Dobashi³, ¹Kagawa University, Kagawa, Japan, ²Kagawa University, Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa, Japan, ³Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan, ⁴Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Kidagun, Japan, ⁵Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Japan, ⁶Kagawa University, Miki-cho, Kita-gun, Japan, ⁷Kagawa University, Miki, Kita District, Kagawa, Japan
Background/Purpose: Pregnancies complicated by systemic lupus erythematosus (SLE) are known to be at high risk for adverse pregnancy outcomes (APOs). Previous studies have shown that…
Abstract Number: 0979 • ACR Convergence 2023
Use and Discontinuation of Tumour Necrosis Factor Inhibitors Among Pregnant Women with Chronic Inflammatory Diseases
Leah K. Flatman¹, Sasha Bernatsky², Isabelle Malhamé³, Yvan St. Pierre², Olga Basso¹, Anick Bérard⁴ and Evelyne Vinet⁵, ¹McGill University, Montreal, QC, Canada, ²Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³McGill University Health Centre, Montreal, QC, Canada, ⁴University of Montreal, Montreal, QC, Canada, ⁵McGill University Health Centre, Montréal, QC, Canada
Background/Purpose: Early consensus statements recommended discontinuing tumour necrosis factor inhibitors (TNFi) during pregnancy. Despite new guidelines recommending against this, the choice to stop TNFi pre-conception…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].